Insulet Corporation (PODD)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $10.58B
Last updated: Nov 17, 2026 at 11:06 AM ET
Insulet Corporation (PODD) Financials: Revenue, Profit and Cash Flow
Insulet reported revenue of $2.71B for the fiscal year ended Dec 31, 2025, up 30.7% from the year before. That year, net income was $247.10M with a net margin of 9.1%, operating cash flow was $569.30M and free cash flow was $358.50M. The quarter ended Sep 30, 2026 had revenue of $842.00M and net income of $141.10M.
Revenue and Margins
The operating margin was 17.5% in the fiscal year ended Dec 2025, the highest of the 10 years shown. Over the 9 years to Dec 2025, revenue grew from $366.99M, a compound annual rate of 24.9%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $2.71B | +30.7% | 71.6% | 17.5% | 9.1% |
| Dec 2024 | $2.07B | +22.1% | 69.8% | 14.9% | 20.2% |
| Dec 2023 | $1.70B | +30.0% | 68.3% | 13.0% | 12.2% |
| Dec 2022 | $1.31B | +18.8% | 61.7% | 2.9% | 0.4% |
| Dec 2021 | $1.10B | +21.5% | 68.4% | 11.5% | 1.5% |
| Dec 2020 | $904.40M | +22.5% | 64.4% | 5.7% | 0.8% |
| Dec 2019 | $738.20M | +30.9% | 65.1% | 6.8% | 1.6% |
| Dec 2018 | $563.80M | +21.6% | 65.7% | 4.9% | 0.6% |
| Dec 2017 | $463.80M | +26.4% | 59.8% | -1.6% | -5.8% |
| Dec 2016 | $366.99M | N/A | 57.5% | -2.9% | -7.9% |
Income Statement
In the fiscal year ended Dec 2025, net income fell 40.9% from the year before. In the quarter ended Sep 2026, net income rose 61.1% from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.71B | $2.07B | $1.70B | $1.31B | $1.10B | $904.40M | $738.20M | $563.80M | $463.80M | $366.99M |
| Cost of revenue | $768.20M | $625.90M | $537.20M | $499.70M | $346.70M | $322.10M | $257.90M | $193.60M | $186.60M | $155.90M |
| Gross profit | $1.94B | $1.45B | $1.16B | $805.60M | $752.10M | $582.30M | $480.30M | $370.20M | $277.20M | $211.09M |
| Research and development | $301.10M | $219.60M | $205.00M | $180.20M | $160.10M | $146.80M | $132.30M | $94.80M | $75.70M | $55.71M |
| Operating income | $473.80M | $308.90M | $220.10M | $37.60M | $126.00M | $51.50M | $50.00M | $27.40M | -$7.40M | -$10.70M |
| Net income | $247.10M | $418.30M | $206.30M | $4.60M | $16.80M | $6.80M | $11.60M | $3.30M | -$26.80M | -$28.88M |
| EBITDA | $584.70M | $391.50M | $301.80M | $105.50M | $221.70M | $155.40M | $114.40M | $71.40M | $27.10M | $14.02M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $842.00M | $801.70M | $761.70M | $783.70M | $706.30M | $649.10M | $569.00M | $597.50M | $543.90M | $488.50M | $441.70M | $509.80M |
| Gross profit | $632.10M | $562.60M | $529.10M | $568.60M | $510.10M | $452.20M | $409.00M | $430.90M | $377.10M | $330.90M | $306.80M | $361.20M |
| Operating income | $189.80M | $129.70M | $122.10M | $146.20M | $117.70M | $121.10M | $88.80M | $109.40M | $88.10M | $54.50M | $56.90M | $106.50M |
| Net income | $141.10M | $95.00M | $91.10M | $101.60M | $87.60M | $22.50M | $35.40M | $100.70M | $77.50M | $188.60M | $51.50M | $103.30M |
Balance Sheet
As of Dec 2025, total debt of $949.20M exceeded cash and equivalents by $233.10M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.19B | $3.09B | $2.59B | $2.25B | $2.05B | $1.87B | $1.14B | $928.70M | $816.74M | $456.65M |
| Current assets | $1.91B | $1.89B | $1.58B | $1.31B | $1.33B | $1.25B | $591.00M | $461.30M | $537.17M | $369.96M |
| Cash and equivalents | $716.10M | $953.40M | $704.20M | $674.70M | $791.60M | $907.20M | $213.70M | $113.90M | $272.58M | $137.17M |
| Total liabilities | $1.68B | $1.88B | $1.86B | $1.77B | $1.49B | $1.27B | $1.07B | $716.60M | $658.23M | $393.50M |
| Short-term debt | $18.40M | $83.80M | $49.40M | $27.50M | $25.10M | $15.60M | $0 | N/A | $566.17M | $269.00K |
| Long-term debt | $930.80M | $1.30B | $1.37B | $1.37B | $1.25B | $1.04B | $887.90M | $592.00M | $566.17M | $332.77M |
| Shareholder equity | $1.52B | $1.21B | $732.70M | $476.40M | $556.30M | $603.60M | $75.90M | $212.10M | $158.52M | $63.15M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $3.42B | $3.17B | $2.99B | $3.19B | $3.03B | $3.47B | $3.52B | $3.09B | $3.03B | $2.88B | $2.62B | $2.59B |
| Total liabilities | $1.84B | $1.74B | $1.68B | $1.68B | $1.65B | $2.01B | $2.19B | $1.88B | $1.91B | $1.88B | $1.83B | $1.86B |
| Cash and equivalents | $584.40M | $534.90M | $480.40M | $716.10M | $757.40M | $1.12B | $1.28B | $953.40M | $902.60M | $821.00M | $751.20M | $650.70M |
| Shareholder equity | $1.58B | $1.42B | $1.30B | $1.52B | $1.38B | $1.46B | $1.33B | $1.21B | $1.12B | $998.40M | $790.70M | $732.70M |
Cash Flow
In the fiscal year ended Dec 2025, free cash flow was 63.0% of operating cash flow. Share repurchases came to 16.6% of it.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $569.30M | $430.20M | $145.70M | $119.00M | -$68.10M | $84.00M | $98.40M | $35.90M | $41.30M | $15.91M |
| Capital expenditures | $210.80M | $134.00M | $84.10M | $135.80M | $122.70M | $166.50M | $163.70M | $157.40M | $73.80M | $22.11M |
| Free cash flow | $358.50M | $296.20M | $61.60M | -$16.80M | -$190.80M | -$82.50M | -$65.30M | -$121.50M | -$32.50M | -$6.20M |
| Dividends paid | N/A | N/A | $10.60M | N/A | $23.50M | $98.50M | $8.60M | N/A | $0 | $0 |
| Share repurchases | $59.60M | $0 | $0 | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing cash flow | -$222.70M | -$146.20M | -$119.40M | -$191.10M | -$82.70M | $14.00M | -$73.60M | -$184.50M | -$210.80M | -$178.01M |
| Financing cash flow | -$595.30M | -$28.00M | -$13.60M | -$40.30M | $40.70M | $605.50M | $73.50M | -$8.70M | $304.50M | $176.57M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $123.50M | $88.40M | $113.80M | $183.30M | $125.70M | $196.50M | $63.80M | $147.50M | $108.30M | $86.80M | $87.60M | $45.20M |
| Capital expenditures | $61.90M | $37.30M | $27.80M | $140.80M | $31.10M | $23.20M | $15.70M | $56.00M | $29.10M | $24.90M | $24.00M | $31.60M |
| Free cash flow | $61.60M | $51.10M | $86.00M | $42.50M | $94.60M | $173.30M | $48.10M | $91.50M | $79.20M | $61.90M | $63.60M | $13.60M |
Frequently Asked Questions About PODD
What is Insulet's annual revenue?
Insulet reported revenue of $2.71B for the fiscal year ended Dec 31, 2025.
How fast is Insulet's revenue growing?
Revenue was up 30.7% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 27.5%.
Is Insulet profitable?
Yes. Insulet reported net income of $247.10M for the fiscal year ended Dec 31, 2025, with a net margin of 9.1%.
How much free cash flow does PODD generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of $569.30M minus capital expenditures of $210.80M produced free cash flow of $358.50M.
How much debt does Insulet have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $930.80M, short-term debt of $18.40M and cash and equivalents of $716.10M.
PODD pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors